Exelixis (NASDAQ:EXEL – Get Rating) and BioNTech (NASDAQ:BNTX – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership. Risk & Volatility Exelixis has a beta of 0.68, meaning that its […]
Exelixis (NASDAQ:EXEL – Get Rating) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Thursday. EXEL has been the topic of several other research reports. EF Hutton Acquisition Co. I reissued a “buy” rating and set a $24.00 target price on shares of […]
Stephens Investment Management Group LLC trimmed its stake in Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 0.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,047,250 shares of the biotechnology company’s stock after selling 25,961 shares during the quarter. Exelixis accounts for 1.1% […]
StockNews.com upgraded shares of Exelixis (NASDAQ:EXEL – Get Rating) from a hold rating to a buy rating in a research report report published on Wednesday. EXEL has been the subject of several other reports. EF Hutton Acquisition Co. I reiterated a buy rating and set a $24.00 target price on shares of Exelixis in a […]
StockNews.com upgraded shares of Exelixis (NASDAQ:EXEL – Get Rating) from a hold rating to a buy rating in a research note released on Wednesday. Several other analysts also recently issued reports on the stock. Piper Sandler reissued an overweight rating and set a $32.00 target price on shares of Exelixis in a research note on […]